Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023GlobeNewsWire • 06/05/23
May MDA Breakout Stocks/ETFs Week 21 - 2023: High-Frequency Gainers To Give You An EdgeSeeking Alpha • 05/21/23
Allakos Provides Business Update and Reports First Quarter 2023 Financial ResultsGlobeNewsWire • 05/09/23
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewsWire • 03/06/23
Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications BiologyGlobeNewsWire • 11/29/22
Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer's 37th Annual MeetingGlobeNewsWire • 11/10/22
Allakos Provides Business Update and Reports Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/07/22
Allakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)GlobeNewsWire • 09/12/22
Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic DuodenitisGlobeNewsWire • 09/09/22
Allakos Provides Business Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/04/22
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.- ALLKNewsfile Corp • 06/15/22
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.- ALLKNewsfile Corp • 06/14/22
INVESTIGATION NOTICE: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Management of Allakos Inc.- ALLKNewsfile Corp • 06/13/22
Allakos Provides Business Update and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/06/22
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/01/22